Ph 2 Study of IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Conditions: Melanoma Stage III; Melanoma Stage IV; Inoperable Disease Interventions: Drug: Interleukin-2; Drug: Ipilimumab; Drug: Nivolumab Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Clinigen Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials